Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
about
NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer modelsSynthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancerAdvances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancersPhase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemiaActivation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatmentExpression-based Pathway Signature Analysis (EPSA): mining publicly available microarray data for insight into human disease.Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumorsPhase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumorsTanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.An AlphaScreen-based high-throughput screen to identify inhibitors of Hsp90-cochaperone interaction.Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma19-substituted benzoquinone ansamycin heat shock protein-90 inhibitors: biological activity and decreased off-target toxicity.Heat shock protein 90β stabilizes focal adhesion kinase and enhances cell migration and invasion in breast cancer cellsHSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humansHeat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemiasAnticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.Identification and characterisation of a novel heat shock protein 90 inhibitor ONO4140.Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancerSNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinomaTipifarnib and tanespimycin show synergic proapoptotic activity in U937 cellsHeat shock protein 90 inhibition in lung cancer.A novel class of small molecule inhibitors of Hsp90.Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.First Structural View of a Peptide Interacting with the Nucleotide Binding Domain of Heat Shock Protein 90Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG.A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancerSynergistic combinations of multiple chemotherapeutic agents in high capacity poly(2-oxazoline) micellesA 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs.Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.Hsp90 inhibitor partially corrects nephrogenic diabetes insipidus in a conditional knock-in mouse model of aquaporin-2 mutation.VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancerMolecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesotheliomaNew developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.HER2 breast cancer therapies: a reviewThe novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors
P2860
Q21195221-D8F41CE7-BDC3-4923-B9AC-DD3A8506D112Q24657439-7D6CEA3B-FD47-44A4-956B-CB611A622A3BQ27022514-C06F72D7-A273-44FB-B83D-4A1CCA9D66E7Q28271726-A16BF02F-0A27-4060-8B52-E3B24C40F439Q28472376-EB89C218-1533-48DF-9B91-47A13FDAC484Q28477468-11F2365F-838F-4A70-97A8-5AC35B4CB193Q33378247-35EC85D5-13BB-4BE0-8C47-FBA4CBC7236BQ33387877-6E10C688-71AD-455D-80BD-DA330B907119Q33388351-55C5667C-5482-46C1-B573-88E3016DA467Q33390600-C40B9F85-1C93-4C9B-ABEC-AF410AF995F0Q33397124-55E8F66E-87F2-430E-8DE6-519C4CF2207FQ33408481-67049146-2082-45F7-BB50-EABDC77ED2EDQ33440318-2B6BA2EC-344D-493A-9187-014AF87F03ECQ33584583-A00AA992-26E5-4438-8ECA-7A45384EEB69Q33998634-A5A879D8-179F-476D-8394-A56C9458FD40Q34162151-79607942-AF1E-4B58-AFBB-495AA5378608Q34374079-DF528650-F0CF-4F5C-93C1-24D56684414CQ34616517-F1D38F87-CA70-41A1-9A7B-7342FF18C800Q35169884-7136E2DA-316C-4778-84F8-842B5497CF0EQ35194754-2ED430F8-1635-49F7-8D5F-46B48408A589Q35469447-B0D3287A-21A6-455D-BD19-95174097AC26Q35691439-D130E5AB-1F31-4E72-882D-DBACC971404BQ35754391-6DB0A90F-A324-44D4-86AD-6E7C63B2376AQ35762499-A8AD1C33-06B5-4873-A6FF-1EA3A090D1C1Q35764444-618B05BA-1A72-4279-9DB1-0B2A618E676DQ36162690-B5324B0A-439C-4540-B8AC-1DB02BC6E301Q36310262-C4C7F636-779F-4C8E-B792-F0EAB51923B4Q36312850-7C082658-372D-4458-8CA5-B5CDE9E1530DQ36316817-FC3464B3-A221-45F3-98BB-5CE313C5FCE7Q36325610-D638D9A4-ED7D-4C2E-9FF8-337055DF214AQ36501393-0A75CE89-AD86-4AF7-B3C4-FECAD91F573FQ36976738-DB63BC84-E4DE-42FF-963C-AB328A165C8AQ37068863-85136379-D8CC-4B55-BB70-B3958093DF91Q37072437-8ABE220F-851B-49F6-8EF9-81410444084DQ37075370-E81B2F58-D773-4B30-8B3C-2E85512A945FQ37092020-FA898287-E8AC-4463-B6A9-93B3FD6273C0Q37130217-6DA994D6-0AD2-48C7-912D-7AED9E135922Q37215989-389BBFF0-88DE-41DA-B1D2-EAD8F38469D8Q37303196-864D94E9-A0F2-43F5-B54A-85965E322B70Q37333665-C51FD657-F52D-4D7F-BC66-FC1EE10A188D
P2860
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
@ast
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
@en
type
label
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
@ast
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
@en
prefLabel
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
@ast
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
@en
P2093
P2860
P1476
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
@en
P2093
Anthony DeLaCruz
Catherine Kopil
David B Solit
Glenn Heller
Howard I Scher
Lawrence Schwartz
Merrill J Egorin
Michael J Morris
Neal Rosen
Rachel Sikorski
P2860
P304
P356
10.1158/1078-0432.CCR-06-1863
P407
P577
2007-03-01T00:00:00Z